Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Leukemia
•
Hematology
How do you incorporate non-Tier I NGS variants in your management of acute leukemias (and other hematologic malignancies)?
Related Questions
With the recent approval of quizartinib, what is your preferred first-line FLT3 inhibitor in combination with chemotherapy for a fit AML patient with a FLT3-ITD mutation?
What is the preferred approach for an AYA patient with VHR B-ALL with iAMP21 mutation with an isolated early CNS relapse?
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
What is the role of post-transplant FLT3 inhibition given the results of BMT-CTN 1506 (MORPHO)?
In what situations do you use G-CSF for patients undergoing allogeneic HSCT to facilitate engraftment?
In a patient with tp53 mutated AML which has been refractory to Van+Aza and FLAG and in a center with limited clinical trial options; what treatment would you offer this patient?
What induction would you choose for a healthy 65 year old with prior chemo/RT for H&N cancer 2 years ago, now with FLT3-ITD+ (0.25) and inv(16) AML?
Would you re challenge a CLL patient, who had good response to Zanubrutinib but contracted cryptococcal pneumonia, with another TKI?
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
Do complex cytogenetics have any therapeutic or prognostic relevance in CLL?
